Carsten Utoft Niemann, MD, PhD, Copenhagen University Hospital, discusses results from the GLOW clinical trial in chronic lymphocytic leukemia (CLL).
CLL is a rare cancer of the lymphocytes. Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and frequent infections. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. The underlying cause is thought to be a combination of genetic and other unknown factors.
The GLOW clinical trial is a randomized, open-label, phase 3 study evaluating progression free survival (PFS) of ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) in patients with CLL.
Ibr+Ven was observed to prolong PFS with a rate of 59.9% and reduce the risk of progression or death by 73%. This is compared to a 17.8% PFS rate with Clb+O. Prolonged PFS rates with Ibr+Ven were independent of IGHV status.
Additionally, when compared to Clb+O, Ibr+Ven prolonged time to next treatment, reduced the need for second-line therapy, prolonged overall survival, reduced the relative risk of death by 54%, and prolonged time spent without toxicity or progression.
For more information, click here.
To learn more about CLL and other rare cancers, visit https://checkrare.com/diseases/cancers/
